These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28456734)

  • 1. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
    Siu L; Brody J; Gupta S; Marabelle A; Jimeno A; Munster P; Grilley-Olson J; Rook AH; Hollebecque A; Wong RKS; Welsh JW; Wu Y; Morehouse C; Hamid O; Walcott F; Cooper ZA; Kumar R; Ferté C; Hong DS
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
    Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
    Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin.
    Xie MH; Ge M; Peng JB; Jiang XR; Wang DS; Ji LQ; Ying Y; Wang Z
    Pharm Dev Technol; 2019 Jun; 24(5):623-629. PubMed ID: 30457414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model.
    Cespi M; Bonacucina G; Pucciarelli S; Cocci P; Perinelli DR; Casettari L; Illum L; Palmieri GF; Palermo FA; Mosconi G
    Eur J Pharm Biopharm; 2014 Nov; 88(3):954-61. PubMed ID: 25194925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
    Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
    Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
    Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
    Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
    Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
    J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
    Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
    Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
    Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist.
    Akash MS; Rehman K; Sun H; Chen S
    Pharm Dev Technol; 2014 May; 19(3):278-84. PubMed ID: 23506246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
    Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
    J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
    Kim H; Griffith TS; Panyam J
    J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
    Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
    Front Immunol; 2020; 11():580974. PubMed ID: 33262759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
    McGowan DC; Herschke F; Khamlichi MD; Rosauro ML; Benedicto SMP; Pauwels F; Stoops B; Pande V; Scholliers A; Van Schoubroeck B; Mostmans W; Van Dijck K; Thoné T; Horton H; Fanning G; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3216-3221. PubMed ID: 30143425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
    Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
    Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.
    Kasturi SP; Rasheed MAU; Havenar-Daughton C; Pham M; Legere T; Sher ZJ; Kovalenkov Y; Gumber S; Huang JY; Gottardo R; Fulp W; Sato A; Sawant S; Stanfield-Oakley S; Yates N; LaBranche C; Alam SM; Tomaras G; Ferrari G; Montefiori D; Wrammert J; Villinger F; Tomai M; Vasilakos J; Fox CB; Reed SG; Haynes BF; Crotty S; Ahmed R; Pulendran B
    Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32561559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermosensitive micelles-hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel.
    Ju C; Sun J; Zi P; Jin X; Zhang C
    J Pharm Sci; 2013 Aug; 102(8):2707-17. PubMed ID: 23839931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.